Amgen Inc. (NASDAQ:AMGN) Shares Sold by Oliver Lagore Vanvalin Investment Group

Oliver Lagore Vanvalin Investment Group lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 11.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 432 shares of the medical research company’s stock after selling 54 shares during the period. Oliver Lagore Vanvalin Investment Group’s holdings in Amgen were worth $135,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in AMGN. Aveo Capital Partners LLC raised its holdings in shares of Amgen by 19.9% in the 4th quarter. Aveo Capital Partners LLC now owns 2,729 shares of the medical research company’s stock valued at $786,000 after purchasing an additional 453 shares in the last quarter. Gryphon Financial Partners LLC raised its stake in Amgen by 295.3% in the fourth quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock valued at $1,021,000 after buying an additional 2,752 shares in the last quarter. Madison Asset Management LLC lifted its holdings in Amgen by 10.1% during the 4th quarter. Madison Asset Management LLC now owns 7,644 shares of the medical research company’s stock worth $2,202,000 after buying an additional 700 shares during the last quarter. Partners Capital Investment Group LLP boosted its position in shares of Amgen by 5.2% during the 4th quarter. Partners Capital Investment Group LLP now owns 1,264 shares of the medical research company’s stock worth $364,000 after acquiring an additional 62 shares in the last quarter. Finally, Rathbones Group PLC increased its holdings in shares of Amgen by 2.1% in the 4th quarter. Rathbones Group PLC now owns 9,112 shares of the medical research company’s stock valued at $2,624,000 after acquiring an additional 184 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 1.1 %

Shares of NASDAQ AMGN opened at $322.67 on Friday. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85. The company has a market capitalization of $173.09 billion, a PE ratio of 46.10, a price-to-earnings-growth ratio of 2.98 and a beta of 0.61. The firm’s 50-day moving average is $328.77 and its two-hundred day moving average is $307.54.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. During the same quarter last year, the company posted $5.00 earnings per share. Amgen’s revenue for the quarter was up 20.1% on a year-over-year basis. Equities analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.79%. Amgen’s payout ratio is currently 128.57%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AMGN. TD Cowen upped their price target on Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Oppenheimer restated an “outperform” rating and issued a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. Morgan Stanley cut their price target on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. Bank of America lifted their price target on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $325.55.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.